Enliven Therapeutics, Inc. · NASDAQ:ELVN
Collins Helen Louise sold 5,000 Enliven Therapeutics, Inc. shares (Form 4)
Traded Aug 17, 2026 · Filed Aug 19, 2026
On Aug 17, 2026, Collins Helen Louise (CHIEF MEDICAL OFFICER) sold 5,000 Enliven Therapeutics, Inc. shares at an average US$58.59 for US$293K under a trading plan, leaving 25,000 shares. Filed Aug 19, 2026 (Form 4).
- Sold
- 5,000 shares
- Price
- US$58.59 average (US$58.37 to US$59.35)
- Value
- US$293K
- Holding after
- 25,000 shares
- Trading plan
- Yes (Made under a plan set in advance)
- Role
- CHIEF MEDICAL OFFICER
The filing in full
| Date | Security | Transaction | Shares | Price | Holding after | Ownership |
|---|---|---|---|---|---|---|
| Aug 17, 2026 | Common Stock | Option exercise | 5,000 | US$2.48 | 30,000 | Direct |
| Aug 17, 2026 | Common Stock | Sale | 3,900 | US$58.37 | 26,100 | Direct |
| Aug 17, 2026 | Common Stock | Sale | 1,100 | US$59.35 | 25,000 | Direct |
Source
Related
- Enliven Therapeutics, Inc.
- Collins Helen Louise
- Enliven Therapeutics, Inc. shareholders
- Form 4 · Collins Helen Louise · Oct 21, 2026
- Form 4 · Collins Helen Louise · Sep 21, 2026
- Form 4 · Collins Helen Louise · Jul 21, 2026
- Form 4 · Collins Helen Louise · Jun 22, 2026
- Form 4 · Collins Helen Louise · May 20, 2026
- Form 4 · Hohl Benjamin · Oct 21, 2026
- Form 4 · Garland J. Scott · Oct 5, 2026
- Form 4 · Hohl Benjamin · Sep 21, 2026
- Form 4 · Hohl Benjamin · Aug 19, 2026
- Form 4 · Derynck Mika K · Aug 6, 2026